fr   en
Agreements
Select a partner :
Type of agreement :





Select a compound/Disease :
Choose date:
[<<]      «      1   |   2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11      »      [65]
Date Partners Compound / Disease area / Development phase Type of agreement Nature / Financial terms
2010-08-24 Kamada Ltd (Israel)

Baxter (USA)
Glassia® (human Alpha 1-Proteinase Inhibitor)
/ emphysema due to congenital deficiency of alpha 1-proteinase inhibitor (Alpha 1-PI), also known as alpha 1-antitrypsin (AAT) deficiency
commercialization/ distribution
See details
2010-08-24 Aileron Therapeutics (USA)

Roche (Switzerland)
stapled peptide therapeutics
This new kind of peptides is the result of Aileron’s peptide stabilization technology. Aileron’s proprietary technology platform “locks” peptides into their biologically active shape, mimicking the structures found in nature. This process captures the best features of both small molecules and therapeutic proteins, ultimately endowing the peptide with unique and beneficial drug-like properties, including efficient cell penetration, improved pharmacokinetics, high-affinity binding to large target protein surfaces and excellent stability within the body.
This could expand the number of "druggable" therapeutic targets, by providing an opportunity to address the thousands of intracellular protein-protein interactions that remain a challenge for functional modulation by current therapeutics. / oncology, virology, inflammation, metabolism and CNS
R&D
commercialization/ distribution
development
See details
2010-08-18 CEVEC Pharmaceuticals (Germany)
Life Technologies Corporation (USA)

Human CAP-T® Technology
The CAP-T protein production technology is based on CAP cells, a human immortalized cell line for stable protein production derived from amniocytes. CAP cells are optimized to growth in serum-free suspension cultures and show human-like post-translational modifications including authentic human glycosylation patterns.
licensing
See details
2010-08-11 PregLem (Switzerland)

Merck Serono (Germany- Switzerland)
Bentamapimod (orally active Jun Kinase Inhibitor, JNK-I AS602801) / prevention of post-surgical abdominal adhesions and endometriosis in patients with tubal ligation or comparable effective contraception
licensing
See details
2010-08-10 NsGene (Denmark)
Biogen Idec (USA)

Neublastin (disease-modifying therapeutic protein) / neuropathic pain licensing
commercialization/ distribution
development
See details
2010-08-05 Lonza (Switzerland)
Roslin Cells Ltd (UK)
Customized cell culture media and processes for the production of pluripotent stem cells in the field of cell therapy
R&D
development
See details
2010-08-04 Proximagen (UK)
BrainCells (USA)

Sabcomeline (muscarinic partial agonist)
/ Psychiatric and neurologic disorders
other
See details
2010-08-03 Telormedix (Switzerland)
Swiss Tropical and Public Health Institute (Swiss TPH - Switzerland)

TMX-201
This second generation TLR7 molecule is intended to act as an activator of the innate immune system and enhance the process of immunisation.
/ Malaria and Buruli Ulcer
R&D
other
See details
2010-07-29 SynCo Bio Partners (The Netherlands)
Versatis (USA)
VRS-317 (once monthly form of human growth hormone)
/ growth hormone deficiency
manufacturing
See details
2010-07-27 Protaffin (Austria)
CMC Biologics (Denmark/USA)

PA401 (glycan-binding decoy protein based on human chemokine IL-8 - CXCL8)
A composition of matter patent covering PA401 has been granted in the USA and the EU.
/ chronic obstructive pulmonary disease (COPD)
manufacturing
See details
2010-07-26 NovImmune (Switzerland)
Genentech (USA)

anti-IL17 fully human monoclonal antibody and back-up antibodies licensing
See details
2010-07-22 Algeta (Norway)
Institute for Energy Technology (Norway)

Alpharadin® (radium-223 chloride) / cancer manufacturing
See details
2010-07-22 Algeta (Norway)

Bayer Schering Pharma (Germany)
Alpharadin® (radium-223 chloride) / cancer manufacturing
commercialization/ distribution
See details
2010-07-20 Selvita (Poland)

Rottapharm Madaus (Italy)
Drug discovery services R&D
other
See details
2010-07-19 MediGene (Germany)

Astellas Pharma (Japan)
Eligard® (leuprolide acetate)
/ hormone-dependent prostate cancer
licensing
other
See details
[<<]      «      1   |   2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11      »      [65]